Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma

Why did Tesla shares fall after Musk's new party announcement? How will Trump's new tariffs affect Japan and South Korea? What impact will Meta hiring Apple's AI exec have? Why is CoreWeave acquiring Core Scientific for $9 billion? How are Amazon and Walmart competing during Prime Day? What caused Samsung’s large Q2 profit decline? Why are German companies planning major investments now?

Regeneron’s Lynozyfic Gains Accelerated FDA Approval for Multiple Myeloma

finance.yahoo.com/news/regeneron-lynozyfic-gains-accelerated-fda-093202979.html

In This Article:
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On July 2, the US FDA) granted accelerate approval to Regeneron Pharmaceuticals’s linvoseltamab-gcpt, which is marketed under the brand name…

This story appeared on finance.yahoo.com, 2025-07-08 09:32:02.